Cure My Disease

Don't miss your cure!

 Log in / Sign up

Portuguese study reveals how benralizumab works in real life for severe asthma

NCT ID NCT07159295

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked back at medical records of 74 adults in Portugal with severe eosinophilic asthma who were treated with benralizumab. Researchers wanted to describe patient characteristics, treatment patterns, and outcomes in real-world settings. The study did not test a new treatment but gathered information to understand how benralizumab is used outside of clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
benralizumab
What this could lead to
If successful, this study could help doctors understand how well benralizumab works in everyday practice for severe asthma patients in Portugal.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to other countries or populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

74 people

The number who actually took part.

Started

Aug 2021

Finished

Nov 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Severe eosinophilic asthma patients aged 18 and above, treated with benralizumab and who have had their first benralizumab dose between July 2019 and October 2020 and who have at least 1 benralizumab injection and with at least 3 months follow-up data from the first injection.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults patients with severe asthma treated with benralizumab, who had their first benralizumab dose between July 2019 and October 2020 * Patients who have at least 1 benralizumab injection and with at least 3 months follow-up data from the first injection. * Give voluntary signed informed consent Exclusion Criteria: * Currently receiving benralizumab or any other biologic drug for the treatment of asthma in a clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Severe asthma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma chronic asthma T2-high asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Severe asthma

Contacts and locations

Locations

  • CHTMAD

    Vila Real, 5000-508, Portugal

  • CHUA

    Faro, 8000-368, Portugal

  • CHUA

    Portimão, 8500-338, Portugal

  • CHUC - Imunoalergologia

    Coimbra, 3000 -076, Portugal

  • CHUC - Pneumologia

    Coimbra, 3000 -076, Portugal

  • CHUSJ - Imuno

    Porto, 4200 - 319, Portugal

  • CHUSJ - Pneumo

    Porto, 4200 - 319, Portugal

  • CHVNGE

    Vila Nova de Gaia, 4430 - 999, Portugal

  • Chln - Hsm

    Lisbon, 1649-035, Portugal

  • Chuln - Hsm

    Lisbon, 1649-035, Portugal

  • Chusj - Cri

    Porto, 4200-319, Portugal

  • HSMM

    Barcelos, 4750-275, Portugal

  • Hospital Distrital de Santarém

    Santarém, 2005-177, Portugal

  • Hospital Leiria

    Leiria, 2410-197, Portugal

  • Hospital Pedro Hispano

    Matosinhos Municipality, 4464-513, Portugal

  • Hospital Prof. Dr. Fernando Fonseca

    Amadora, 2720-276, Portugal

More trials for these conditions

Other studies related to the condition(s) this trial covers.